Spotlight on nilotinib in the treatment of chronic myelogenous leukemia

Stephen Harnicar, Sherry Mathew Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA Abstract: Nowhere has targeted therapy been more successful in the hematologic malignancy arena than chronic myelogenous leukemia (CML). By targeting the BCR–ABL fusion oncog...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Harnicar S, Mathew S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/86bb35367d5e4a31b6d06b29616cc28c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:86bb35367d5e4a31b6d06b29616cc28c
record_format	dspace
spelling	oai:doaj.org-article:86bb35367d5e4a31b6d06b29616cc28c2021-12-02T00:36:48ZSpotlight on nilotinib in the treatment of chronic myelogenous leukemia1179-9889https://doaj.org/article/86bb35367d5e4a31b6d06b29616cc28c2014-08-01T00:00:00Zhttp://www.dovepress.com/spotlight-on-nilotinib-in-the-treatment-of-chronic-myelogenous-leukemi-peer-reviewed-article-BLCTThttps://doaj.org/toc/1179-9889 Stephen Harnicar, Sherry Mathew Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA Abstract: Nowhere has targeted therapy been more successful in the hematologic malignancy arena than chronic myelogenous leukemia (CML). By targeting the BCR–ABL fusion oncogene, the introduction of tyrosine-kinase inhibitors (TKIs) has dramatically improved the outcomes of this disease. Nilotinib is a second-generation TKI that initially gained approval for the treatment of imatinib-resistant or -intolerant disease for patients with chronic or accelerated-phase CML. Investigation in the first-line setting also demonstrated efficacy, and expanded nilotinib’s approval to include therapy for patients with treatment-naïve chronic-phase CML. Data also exist for blast-phase disease, which allows nilotinib to be an option for all phases. Nilotinib’s place in therapy is continuously being expanded by research in novel areas, such as post-hematopoietic stem cell transplants for prevention of relapse and in the pediatric arena. With multiple TKIs now approved for the treatment of CML, delineating the pharmacologic distinctions of nilotinib is an asset when determining therapy. By understanding the pharmacokinetics and dependence on hepatic metabolism of nilotinib, the clinician can manage the potential toxicities, interactions, and unique dosing of this drug. The recognition of mechanisms of resistance, patient adherence, and cost-effectiveness are similarly significant considerations. Actively integrating these various specifics will allow clinicians to optimize nilotinib therapy for the CML patient. Keywords: nilotinib, chronic myelogenous leukemia, CML, tyrosine-kinase inhibitor, TKI Harnicar SMathew SDove Medical PressarticleDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol 2014, Iss default, Pp 61-67 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Harnicar S Mathew S Spotlight on nilotinib in the treatment of chronic myelogenous leukemia
description	Stephen Harnicar, Sherry Mathew Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA Abstract: Nowhere has targeted therapy been more successful in the hematologic malignancy arena than chronic myelogenous leukemia (CML). By targeting the BCR–ABL fusion oncogene, the introduction of tyrosine-kinase inhibitors (TKIs) has dramatically improved the outcomes of this disease. Nilotinib is a second-generation TKI that initially gained approval for the treatment of imatinib-resistant or -intolerant disease for patients with chronic or accelerated-phase CML. Investigation in the first-line setting also demonstrated efficacy, and expanded nilotinib’s approval to include therapy for patients with treatment-naïve chronic-phase CML. Data also exist for blast-phase disease, which allows nilotinib to be an option for all phases. Nilotinib’s place in therapy is continuously being expanded by research in novel areas, such as post-hematopoietic stem cell transplants for prevention of relapse and in the pediatric arena. With multiple TKIs now approved for the treatment of CML, delineating the pharmacologic distinctions of nilotinib is an asset when determining therapy. By understanding the pharmacokinetics and dependence on hepatic metabolism of nilotinib, the clinician can manage the potential toxicities, interactions, and unique dosing of this drug. The recognition of mechanisms of resistance, patient adherence, and cost-effectiveness are similarly significant considerations. Actively integrating these various specifics will allow clinicians to optimize nilotinib therapy for the CML patient. Keywords: nilotinib, chronic myelogenous leukemia, CML, tyrosine-kinase inhibitor, TKI
format	article
author	Harnicar S Mathew S
author_facet	Harnicar S Mathew S
author_sort	Harnicar S
title	Spotlight on nilotinib in the treatment of chronic myelogenous leukemia
title_short	Spotlight on nilotinib in the treatment of chronic myelogenous leukemia
title_full	Spotlight on nilotinib in the treatment of chronic myelogenous leukemia
title_fullStr	Spotlight on nilotinib in the treatment of chronic myelogenous leukemia
title_full_unstemmed	Spotlight on nilotinib in the treatment of chronic myelogenous leukemia
title_sort	spotlight on nilotinib in the treatment of chronic myelogenous leukemia
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/86bb35367d5e4a31b6d06b29616cc28c
work_keys_str_mv	AT harnicars spotlightonnilotinibinthetreatmentofchronicmyelogenousleukemia AT mathews spotlightonnilotinibinthetreatmentofchronicmyelogenousleukemia
_version_	1718403629298221056

Spotlight on nilotinib in the treatment of chronic myelogenous leukemia

Ejemplares similares